Quantcast
Home > Quotes > EDAP
EDAP

EDAP TMS S.A. American Depositary Shares (EDAP) Quote & Summary Data

$2.57
*  
0.04
1.53%
Get EDAP Alerts
*Delayed - data as of Dec. 7, 2018  -  Find a broker to begin trading EDAP now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    EDAP Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 2.60 / $ 2.50
Share Volume
40,475
50 Day Avg. Daily Volume
38,635
Previous Close
$ 2.61
52 Week High / Low
$ 4.25 / $ 2.07
Market Cap
74,524,516
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
40,475
50 Day Avg. Daily Volume:
38,635

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.06

Trading Range

The current last sale of $2.57 is 24.15% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.60 $ 4.25
 Low: $ 2.50 $ 2.07

Company Description (as filed with the SEC)

We develop and market the Ablatherm and Focal One devices, advanced choices for HIFU treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option for localized prostate cancer with a low occurrence of side effects. Ablatherm is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option. Focal One is a robot assisted HIFU device dedicated to the focal treatment of prostate cancer. Both HIFU devices are also used for patients who failed a radiotherapy treatment. In addition, we are developing a HIFU platform for the treatment of various types of tumors including rectal endometriosis, liver and pancreatic cancer, but also breast and gynecological tumors. We also produce and commercialize medical equipment for treatment of urinary tract stones using ESWL and distribute other types of urology devices in certain countries.  ... More ...  


Risk Grade

Where does EDAP fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.50
Open Date:
Dec. 7, 2018
Close Price:
$ 2.57
Close Date:
Dec. 7, 2018

Consensus Recommendation

Analyst Info